Immuno-Biological Laboratories Co., Ltd.

<h3 class="smt_head2">3. Dividend Policy</h3><p class="smt_text2" style="orphans:0;widows:0;text-align:justify;padding-left:22.5pt;padding-right:0pt;margin-top:0pt;margin-bottom:0pt;text-indent:9pt;font-family:'ＭＳ 明朝';letter-spacing:0pt;line-height:12pt;">The Company recognizes stable profit returns to shareholders as one of its important management priorities. Our basic policy is to determine dividends by comprehensively considering past consolidated earnings trends, future consolidated earnings forecasts, and various indicators such as dividend payout ratio, dividend yield, and equity ratio. Based on this approach, we have decided not to pay a dividend for the current period, taking into account past consolidated earnings trends and internal reserve levels. For the next fiscal year, we plan to pay an annual dividend of 6 yen per share (consolidated dividend payout ratio of approximately 21.1%). Going forward, we will continue to pursue enhanced corporate value and improved dividend returns to our shareholders.</p><p class="smt_text2" style="orphans:0;widows:0;text-align:justify;padding-left:22.5pt;padding-right:0pt;margin-top:0pt;margin-bottom:0pt;text-indent:9pt;font-family:'ＭＳ 明朝';letter-spacing:0pt;line-height:12pt;font-size:9pt;">The Company has adopted an interim dividend system under Article 454, Paragraph 5 of the Companies Act; however, our basic policy is to pay dividends once per fiscal year as a year-end dividend. The Board of Directors decides on interim dividends, while the General Meeting of Shareholders decides on year-end dividends.</p><p class="smt_text6" style="orphans:0;widows:0;text-align:justify;padding-left:13.5pt;padding-right:0pt;margin-top:0pt;margin-bottom:0pt;text-indent:0pt;font-family:'ＭＳ 明朝';letter-spacing:0pt;line-height:15pt;font-size:15pt;"> </p><p class="smt_text6" style="orphans:0;widows:0;text-align:justify;padding-left:13.5pt;padding-right:0pt;margin-top:0pt;margin-bottom:0pt;text-indent:0pt;font-family:'ＭＳ 明朝';letter-spacing:0pt;line-height:15pt;font-size:15pt;"> </p>

<p>We recognize stable profit returns to shareholders as an important management priority. Our basic policy is to determine dividends by comprehensively considering past performance trends, future earnings forecasts, and key indicators such as dividend payout ratio, dividend yield, and equity ratio. Regarding dividend distributions from retained earnings, our fundamental policy is to pay dividends once per year as a year-end dividend.</p>

Fiscal Year	Type	Interim	Year-End	Total	Payout Ratio
FY2027	Forecast(2026/05/13)	0	7.5	7.5	20.1%
FY2026	Actual(2026/05/13)	0	6	6	17.0%
	Forecast(2025/05/14)	0	6	6	21.1%
FY2025	Actual(2025/05/14)	0	0	0	-
	Forecast(2024/05/14)	0	0	0	-
FY2024	Actual(2024/05/14)	0	0	0	-
	Forecast(2023/05/12)	0	0	0	-
FY2023	Actual(2023/05/12)	0	0	0	-
	Forecast(2022/05/13)	0	0	0	-
FY2022	Actual(2022/05/13)	0	0	0	-
	Forecast(2021/08/06)	0	0	0	-
FY2021	Actual(2021/08/06)	0	0	0	-

Immuno-Biological Laboratories Co., Ltd. (4570) Dividends

Dividend Policy

Dividend per Share

Payout Ratio

Dividend Yield

Dividend History (Forecasts, Revisions, Actuals)